### PART B—RESEARCH AUTHORITY

### §300cc–11. Clinical evaluation units at National Institutes of Health
#### (a) In general
* The Secretary, acting through the Director of the National Cancer Institute and the Director of the National Institute of Allergy and Infectious Diseases, shall for each such Institute establish a clinical evaluation unit at the Clinical Center at the National Institutes of Health. Each of the clinical evaluation units—

  * (1) shall conduct clinical evaluations of experimental treatments for acquired immune deficiency syndrome developed within the preclinical drug development program, including evaluations of methods of diagnosing immune deficiency and evaluations of methods of predicting, diagnosing, preventing, and treating opportunistic cancers and infectious diseases; and

  * (2) may conduct clinical evaluations of experimental treatments for such syndrome that are developed by any other national research institute of the National Institutes of Health or by any other entity.

#### (b) Personnel and administrative support
* (1) For the purposes described in subsection (a), the Secretary, acting through the Director of the National Institutes of Health, shall provide each of the clinical evaluation units required in such subsection—

  * (A)(i) with not less than 50 beds; or

  * (ii) with an outpatient clinical capacity equal to not less than twice the outpatient clinical capacity, with respect to acquired immune deficiency syndrome, possessed by the Clinical Center of the National Institutes of Health on June 1, 1988; and

  * (B) with such personnel, such administrative support, and such other support services as may be necessary.


* (2) Facilities, personnel, administrative support, and other support services provided pursuant to paragraph (1) shall be in addition to the number or level of facilities, personnel, administrative support, and other support services that otherwise would be available at the Clinical Center at the National Institutes of Health for the provision of clinical care for individuals with diseases or disorders.

#### (c) Authorization of appropriations
* For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary.

### §300cc–12. Use of investigational new drugs with respect to acquired immune deficiency syndrome
#### (a) Encouragement of applications with respect to clinical trials
* (1) If, in the determination of the Secretary, there is preliminary evidence that a new drug has effectiveness in humans with respect to the prevention or treatment of acquired immune deficiency syndrome, the Secretary shall, through statements published in the Federal Register—

  * (A) announce the fact of such determination; and

  * (B) with respect to the new drug involved, encourage an application for an exemption for investigational use of the new drug under regulations issued under section 355(i) of title 21.


* (2)(A) The AIDS Research Advisory Committee established pursuant to section 300cc–3 of this title shall make recommendations to the Secretary with respect to new drugs appropriate for determinations described in paragraph (1).

* (B) The Secretary shall, as soon as is practicable, determine the merits of recommendations received by the Secretary pursuant to subparagraph (A).

#### (b) Encouragement of applications with respect to treatment use in circumstances other than clinical trials
* (1) In the case of a new drug with respect to which the Secretary has made a determination described in subsection (a) and with respect to which an exemption is in effect for purposes of section 355(i) of title 21, the Secretary shall—

  * (A) as appropriate, encourage the sponsor of the investigation of the new drug to submit to the Secretary, in accordance with regulations issued under such section, an application to use the drug in the treatment of individuals—

    * (i) who are infected with the etiologic agent for acquired immune deficiency syndrome; and

    * (ii) who are not participating in the clinical trials conducted pursuant to such exemption; and


  * (B) if such an application is approved, encourage, as appropriate, licensed medical practitioners to obtain, in accordance with such regulations, the new drug from such sponsor for the purpose of treating such individuals.


* (2) If the sponsor of the investigation of a new drug described in paragraph (1) does not submit to the Secretary an application described in such paragraph (relating to treatment use), the Secretary shall, through statements published in the Federal Register, encourage, as appropriate, licensed medical practitioners to submit to the Secretary such applications in accordance with regulations described in such paragraph.

#### (c) Technical assistance with respect to treatment use
* In the case of a new drug with respect to which the Secretary has made a determination described in subsection (a), the Secretary may, directly or through grants or contracts, provide technical assistance with respect to the process of—

  * (1) submitting to the Secretary applications for exemptions described in paragraph (1)(B) of such subsection;

  * (2) submitting to the Secretary applications described in subsection (b); and

  * (3) with respect to sponsors of investigations of new drugs, facilitating the transfer of new drugs from such sponsors to licensed medical practitioners.

#### (d) "New drug" defined
* For purposes of this section, the term "new drug" has the meaning given such term in section 321 of title 21.

### §300cc–13. Terry Beirn Community-Based AIDS Research Initiative
#### (a) In general
* After consultation with the Commissioner of Food and Drugs, the Director of the National Institutes of Health, acting through the Director of the National Institute of Allergy and Infectious Diseases, may make grants to public entities and nonprofit private entities concerned with acquired immune deficiency syndrome, and may enter into contracts with public and private such entities, for the purpose of planning and conducting, in the community involved, clinical trials of experimental treatments for infection with the etiologic agent for such syndrome that are approved by the Commissioner of Food and Drugs for investigational use under regulations issued under section 355 of title 21.

#### (b) Requirement of certain projects
* (1) Financial assistance under subsection (a) shall include such assistance to community-based organizations and community health centers for the purpose of—

  * (A) retaining appropriate medical supervision;

  * (B) assisting with administration, data collection and record management; and

  * (C) conducting training of community physicians, nurse practitioners, physicians' assistants and other health professionals for the purpose of conducting clinical trials.


* (2)(A) Financial assistance under subsection (a) shall include such assistance for demonstration projects designed to implement and conduct community-based clinical trials in order to provide access to the entire scope of communities affected by infections with the etiologic agent for acquired immune deficiency syndrome, including minorities, hemophiliacs and transfusion-exposed individuals, women, children, users of intravenous drugs, and individuals who are asymptomatic with respect to such infection.

* (B) The Director of the National Institutes of Health may not provide financial assistance under this paragraph unless the application for such assistance is approved—

  * (i) by the Commissioner of Food and Drugs;

  * (ii) by a duly constituted Institutional Review Board that meets the requirements of part 56 of title 21, Code of Federal Regulations; and

  * (iii) by the Director of the National Institute of Allergy and Infectious Diseases.

#### (c) Participation of private industry, schools of medicine and primary providers
* Programs carried out with financial assistance provided under subsection (a) shall be designed to encourage private industry and schools of medicine, osteopathic medicine, and existing consortia of primary care providers organized to conduct clinical research concerning acquired immune deficiency syndrome to participate in, and to support, the clinical trials conducted pursuant to the programs.

#### (d) Requirement of application
* The Secretary may not provide financial assistance under subsection (a) unless—

  * (1) an application for the assistance is submitted to the Secretary;

  * (2) with respect to carrying out the purpose for which the assistance is to be made, the application provides assurances of compliance satisfactory to the Secretary; and

  * (3) the application otherwise is in such form, is made in such manner, and contains such agreements, assurances, and information as the Secretary determines to be necessary to carry out this section.

#### (e) Authorization of appropriations
* (1) For the purpose of carrying out subsection (b)(1), there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 1989 through 1996.

* (2) For the purpose of carrying out subsection (b)(2), there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 1989 through 1996.

### §300cc–14. Evaluation of certain treatments
#### (a) Establishment of program
* (1) After consultation with the AIDS Research Advisory Committee established pursuant to section 300cc–3 of this title, the Secretary shall establish a program for the evaluation of drugs that—

  * (A) are not approved by the Commissioner of Food and Drugs for the purpose of treatments with respect to acquired immune deficiency syndrome; and

  * (B) are being utilized for such purpose by individuals infected with the etiologic agent for such syndrome.


* (2) The program established under paragraph (1) shall include evaluations of the effectiveness and the risks of the treatment involved, including the risks of foregoing treatments with respect to acquired immune deficiency syndrome that are approved by the Commissioner of Food and Drugs.

#### (b) Authority with respect to grants and contracts
* (1) For the purpose of conducting evaluations required in subsection (a), the Secretary may make grants to, and enter into cooperative agreements and contracts with, public and nonprofit private entities.

* (2) Nonprofit private entities under paragraph (1) may include nonprofit private organizations that—

  * (A) are established for the purpose of evaluating treatments with respect to acquired immune deficiency syndrome; and

  * (B) consist primarily of individuals infected with the etiologic agent for such syndrome.

#### (c) Scientific and ethical guidelines
* (1) The Secretary shall establish appropriate scientific and ethical guidelines for the conduct of evaluations carried out pursuant to this section. The Secretary may not provide financial assistance under subsection (b)(1) unless the applicant for such assistance agrees to comply with such guidelines.

* (2) The Secretary may establish the guidelines described in paragraph (1) only after consulting with—

  * (A) physicians whose clinical practice includes a significant number of individuals with acquired immune deficiency syndrome;

  * (B) individuals who are infected with the etiologic agent for such syndrome; and

  * (C) other individuals with appropriate expertise or experience.

#### (d) Authorization of appropriations
* For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary.

### §300cc–15. Support of international efforts
#### (a) Grants and contracts for research
* (1) Under section 242l of this title, the Secretary, acting through the Director of the National Institutes of Health—

  * (A) shall, for the purpose described in paragraph (2), make grants to, enter into cooperative agreements and contracts with, and provide technical assistance to, international organizations concerned with public health; and

  * (B) may, for such purpose, provide technical assistance to foreign governments.


* (2) The purpose referred to in paragraph (1) is promoting and expediting international research and training concerning the natural history and pathogenesis of the human immunodeficiency virus and the development and evaluation of vaccines and treatments for acquired immune deficiency syndrome and opportunistic infections.

#### (b) Grants and contracts for additional purposes
* After consultation with the Administrator of the Agency for International Development, the Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall under section 242l of this title make grants to, enter into contracts with, and provide technical assistance to, international organizations concerned with public health and may provide technical assistance to foreign governments, in order to support—

  * (1) projects for training individuals with respect to developing skills and technical expertise for use in the prevention, diagnosis, and treatment of acquired immune deficiency syndrome; and

  * (2) epidemiological research relating to acquired immune deficiency syndrome.

#### (c) Special Programme of World Health Organization
* Support provided by the Secretary pursuant to this section shall be in furtherance of the global strategy of the World Health Organization Special Programme on Acquired Immunodeficiency Syndrome.

#### (d) Preferences
* In providing grants, cooperative agreements, contracts, and technical assistance under subsections (a) and (b), the Secretary shall—

  * (1) give preference to activities under such subsections conducted by, or in cooperation with, the World Health Organization; and

  * (2) with respect to activities carried out under such subsections in the Western Hemisphere, give preference to activities conducted by, or in cooperation with, the Pan American Health Organization or the World Health Organization.

#### (e) Requirement of application
* The Secretary may not make a grant or enter into a cooperative agreement or contract under this section unless—

  * (1) an application for such assistance is submitted to the Secretary;

  * (2) with respect to carrying out the purpose for which such assistance is to be provided, the application provides assurances of compliance satisfactory to the Secretary; and

  * (3) the application otherwise is in such form, is made in such manner, and contains such agreements, assurances, and information as the Secretary determines to be necessary to carry out this section.

#### (f) Authorization of appropriations
* For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each fiscal year.

### §300cc–16. Research centers
#### (a) In general
* (1) The Secretary, acting through the Director of the National Institute of Allergy and Infectious Diseases, may make grants to, and enter into contracts with, public and nonprofit private entities to assist such entities in planning, establishing, or strengthening, and providing basic operating support for, centers for basic and clinical research into, and training in, advanced diagnostic, prevention, and treatment methods for acquired immune deficiency syndrome.

* (2) A grant or contract under paragraph (1) shall be provided in accordance with policies established by the Secretary, acting through the Director of the National Institutes of Health, and after consultation with the advisory council for the National Institute of Allergy and Infectious Diseases.

* (3) The Secretary shall ensure that, as appropriate, clinical research programs carried out under paragraph (1) include as research subjects women, children, hemophiliacs, and minorities.

#### (b) Use of financial assistance
* (1) Financial assistance under subsection (a) may be expended for—

  * (A) the renovation or leasing of space;

  * (B) staffing and other basic operating costs, including such patient care costs as are required for clinical research;

  * (C) clinical training with respect to acquired immune deficiency syndrome (including such training for allied health professionals); and

  * (D) demonstration purposes, including projects in the long-term monitoring and outpatient treatment of individuals infected with the etiologic agent for such syndrome.


* (2) Financial assistance under subsection (a) may not be expended to provide research training for which Ruth L. Kirschstein National Research Service Awards may be provided under section 288 of this title.

#### (c) Duration of support
* Support of a center under subsection (a) may be for not more than five years. Such period may be extended by the Director for additional periods of not more than five years each if the operations of such center have been reviewed by an appropriate technical and scientific peer review group established by the Director and if such group has recommended to the Director that such period should be extended.

#### (d) Authorization of appropriations
* For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary.

### §300cc–17. Information services
#### (a) Establishment of program
* The Secretary shall establish, maintain, and operate a program with respect to information on research, treatment, and prevention activities relating to infection with the etiologic agent for acquired immune deficiency syndrome. The program shall, with respect to the agencies of the Department of Health and Human Services, be integrated and coordinated.

#### (b) Toll-free telephone communications for health care entities
* (1) After consultation with the Director of the Office of AIDS Research, the Administrator of the Health Resources and Services Administration, and the Director of the Centers for Disease Control and Prevention, the Secretary shall provide for toll-free telephone communications to provide medical and technical information with respect to acquired immune deficiency syndrome to health care professionals, allied health care providers, and to professionals providing emergency health services.

* (2) Information provided pursuant to paragraph (1) shall include—

  * (A) information on prevention of exposure to, and the transmission of, the etiologic agent for acquired immune deficiency syndrome; and

  * (B) information contained in the data banks established in subsections (c) and (d).

#### (c) Data bank on research information
* (1) After consultation with the Director of the Office of AIDS Research, the Director of the Centers for Disease Control and Prevention, and the National Library of Medicine, the Secretary shall establish a data bank of information on the results of research with respect to acquired immune deficiency syndrome conducted in the United States and other countries.

* (2) In carrying out paragraph (1), the Secretary shall collect, catalog, store, and disseminate the information described in such paragraph. To the extent practicable, the Secretary shall make such information available to researchers, physicians, and other appropriate individuals, of countries other than the United States.

#### (d) Data bank on clinical trials and treatments
* (1) After consultation with the Commissioner of Food and Drugs, the AIDS Research Advisory Committee established under section 300cc–3 of this title, and the Director of the Office of AIDS Research, the Secretary shall, in carrying out subsection (a), establish a data bank of information on clinical trials and treatments with respect to infection with the etiologic agent for acquired immune deficiency syndrome (hereafter in this section referred to as the "Data Bank").

* (2) In carrying out paragraph (1), the Secretary shall collect, catalog, store, and disseminate the information described in such paragraph. The Secretary shall disseminate such information through information systems available to individuals infected with the etiologic agent for acquired immune deficiency syndrome, to other members of the public, to health care providers, and to researchers.

#### (e) Requirements with respect to data bank on clinical trials and treatments
* The Data Bank shall include the following:

  * (1) A registry of clinical trials of experimental treatments for acquired immune deficiency syndrome and related illnesses conducted under regulations promulgated pursuant to section 355 of title 21 that provides a description of the purpose of each experimental drug protocol either with the consent of the protocol sponsor, or when a trial to test efficacy begins. Information provided shall include eligibility criteria and the location of trial sites, and must be forwarded to the Data Bank by the sponsor of the trial not later than 21 days after the approval by the Food and Drug Administration.

  * (2) Information pertaining to experimental treatments for acquired immune deficiency syndrome that may be available under a treatment investigational new drug application that has been submitted to the Food and Drug Administration pursuant to part 312 of title 21, Code of Federal Regulations. The Data Bank shall also include information pertaining to the results of clinical trials of such treatments, with the consent of the sponsor, of such experimental treatments, including information concerning potential toxicities or adverse effects associated with the use or administration of such experimental treatment.

### §300cc–18. Development of model protocols for clinical care of infected individuals
#### (a) In general
* (1) The Secretary, acting through the Director of the National Institutes of Health and after consultation with the Director of the Agency for Healthcare Research and Quality, may make grants to public and nonprofit private entities for the establishment of projects to develop model protocols for the clinical care of individuals infected with the etiologic agent for acquired immune deficiency syndrome, including treatment and prevention of HIV infection and related conditions among women.

* (2) The Secretary may not make a grant under paragraph (1) unless—

  * (A) the applicant for the grant is a provider of comprehensive primary care; or

  * (B) the applicant for the grant agrees, with respect to the project carried out pursuant to paragraph (1), to enter into a cooperative arrangement with an entity that is a provider of comprehensive primary care.

#### (b) Requirement of provision of certain services
* The Secretary may not make a grant under subsection (a) unless the applicant for the grant agrees that, with respect to patients participating in the project carried out with the grant, services provided pursuant to the grant will include—

  * (1) monitoring, in clinical laboratories, of the condition of such patients;

  * (2) clinical intervention for infection with the etiologic agent for acquired immune deficiency syndrome, including measures for the prevention of conditions arising from the infection;

  * (3) information and counseling on the availability of treatments for such infection approved by the Commissioner of Food and Drugs, on the availability of treatments for such infection not yet approved by the Commissioner, and on the reports issued by the AIDS Research Advisory Committee under section 300cc–3(c)(2)(B) of this title;

  * (4) support groups; and

  * (5) information on, and referrals to, entities providing appropriate social support services.

#### (c) Limitation on imposition of charges for services
* The Secretary may not make a grant under subsection (a) unless the applicant for the grant agrees that, if the applicant will routinely impose a charge for providing services pursuant to the grant, the applicant will not impose the charge on any individual seeking such services who is unable to pay the charge.

#### (d) Evaluation and reports
* (1) The Secretary may not make a grant under subsection (a) unless the applicant for the grant agrees, with respect to the project carried out pursuant to subsection (a), to submit to the Secretary—

  * (A) information sufficient to assist in the replication of the model protocol developed pursuant to the project; and

  * (B) such reports as the Secretary may require.


* (2) The Secretary shall provide for evaluations of projects carried out pursuant to subsection (a) and shall annually submit to the Congress a report describing such projects. The report shall include the findings made as a result of such evaluations and may include any recommendations of the Secretary for appropriate administrative and legislative initiatives with respect to the program established in this section.

#### (e) Authorization of appropriations
* For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 1989 through 1991, and such sums as may be necessary for each of the fiscal years 1994 through 1996.

### §300cc–19. National blood resource education program
* After consultation with the Director of the National Heart, Lung, and Blood Institute and the Commissioner of Food and Drugs, the Secretary shall establish a program of research and education regarding blood donations and transfusions to maintain and improve the safety of the blood supply. Education programs shall be directed at health professionals, patients, and the community to—

  * (1) in the case of the public and patients undergoing treatment—

    * (A) increase awareness that the process of donating blood is safe;

    * (B) promote the concept that blood donors are contributors to a national need to maintain an adequate and safe blood supply;

    * (C) encourage blood donors to donate more than once a year; and

    * (D) encourage repeat blood donors to recruit new donors;


  * (2) in the case of health professionals—

    * (A) improve knowledge, attitudes, and skills of health professionals in the appropriate use of blood and blood components;

    * (B) increase the awareness and understanding of health professionals regarding the risks versus benefits of blood transfusion; and

    * (C) encourage health professionals to consider alternatives to the administration of blood or blood components for their patients; and


  * (3) in the case of the community, increase coordination, communication, and collaboration among community, professional, industry, and government organizations regarding blood donation and transfusion issues.

### §300cc–20. Additional authority with respect to research
#### (a) Data collection with respect to national prevalence
* (1) The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may, through representative sampling and other appropriate methodologies, provide for the continuous collection of data on the incidence in the United States of cases of acquired immune deficiency syndrome and of cases of infection with the etiologic agent for such syndrome. The Secretary may carry out the program of data collection directly or through cooperative agreements and contracts with public and nonprofit private entities.

* (2) The Secretary shall encourage each State to enter into a cooperative agreement or contract under paragraph (1) with the Secretary in order to facilitate the prompt collection of the most recent accurate data on the incidence of cases described in such paragraph.

* (3) The Secretary shall ensure that data collected under paragraph (1) includes data on the demographic characteristics of the population of individuals with cases described in paragraph (1), including data on specific subpopulations at risk of infection with the etiologic agent for acquired immune deficiency syndrome.

* (4) In carrying out this subsection, the Secretary shall, for the purpose of assuring the utility of data collected under this section, request entities with expertise in the methodologies of data collection to provide, as soon as is practicable, assistance to the Secretary and to the States with respect to the development and utilization of uniform methodologies of data collection.

* (5) The Secretary shall provide for the dissemination of data collected pursuant to this subsection. In carrying out this paragraph, the Secretary may publish such data as frequently as the Secretary determines to be appropriate with respect to the protection of the public health. The Secretary shall publish such data not less than once each year.

#### (b) Epidemiological and demographic data
* (1) The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall develop an epidemiological data base and shall provide for long-term studies for the purposes of—

  * (A) collecting information on the demographic characteristics of the population of individuals infected with the etiologic agent for acquired immune deficiency syndrome and the natural history of such infection; and

  * (B) developing models demonstrating the long-term domestic and international patterns of the transmission of such etiologic agent.


* (2) The Secretary may carry out paragraph (1) directly or through grants to, or cooperative agreeements or contracts with, public and nonprofit private entities, including Federal agencies.

#### (c) Long-term research
* The Secretary may make grants to public and nonprofit private entities for the purpose of assisting grantees in conducting long-term research into treatments for acquired immune deficiency syndrome developed from knowledge of the genetic nature of the etiologic agent for such syndrome.

#### (d) Social sciences research
* The Secretary, acting through the Director of the National Institute of Mental Health, may make grants to public and nonprofit private entities for the purpose of assisting grantees in conducting scientific research into the psychological and social sciences as such sciences relate to acquired immune deficiency syndrome.

#### (e) Authorization of appropriations
* (1) For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each fiscal year.

* (2) Amounts appropriated pursuant to paragraph (1) to carry out subsection (c) shall remain available until expended.